Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery

Summary

The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.

Timeline

Start

2026-06-10

Primary completion

2028-10-01

Completion

2029-01-01

Drugs

Indications